XML 69 R56.htm IDEA: XBRL DOCUMENT v3.20.2
Geneos Therapeutics, Inc. - Narrative (Details) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended
Jun. 01, 2020
Jun. 30, 2020
Feb. 28, 2019
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Jan. 31, 2020
Dec. 31, 2019
Noncontrolling Interest [Line Items]                  
Gain on deconsolidation of investment       $ 4,121,075 $ 0 $ 4,121,075 $ 0    
Share in net loss of Geneos       (901,757) $ 0 (901,757) $ 0    
Investment in equity method investments   $ 2,717,241   $ 2,717,241   $ 2,717,241     $ 0
Geneos Therapeutics, Inc.                  
Noncontrolling Interest [Line Items]                  
Noncontrolling interest, ownership percentage by parent     61.00%         52.00%  
Ownership percentage   47.00%   47.00%   47.00%      
Geneos Therapeutics, Inc.                  
Noncontrolling Interest [Line Items]                  
Payments to acquire additional interest in subsidiaries     $ 1,200,000            
Stock purchase agreement, commitment of additional investment   $ 800,000   $ 800,000   $ 800,000   $ 800,000  
Gain on deconsolidation of investment $ 4,121,075                
Deconsolidation gain, remeasurement of retained noncontrolling investment to fair value 2,400,000                
Share in net loss of Geneos   (902,000)              
Investment in equity method investments 3,618,998                
Due from related parties   97,000   97,000   97,000      
Geneos Therapeutics, Inc. | Common stock                  
Noncontrolling Interest [Line Items]                  
Share in net loss of Geneos   (819,000)              
Investment in equity method investments 819,000 0   $ 0   $ 0      
Geneos Therapeutics, Inc. | Preferred stock                  
Noncontrolling Interest [Line Items]                  
Share in net loss of Geneos   $ (83,000)              
Investment in equity method investments $ 2,799,998